)
Miguel Arcinas
Venture Partner
RA Ventures
Miguel Arcinas is a Venture Partner at RA Ventures, leading the corporate development function for various portfolio companies. He most recently served as Chief Business Officer of Capstan Therapeutics, which was acquired by AbbVie in 2025. He brings more than 15 years of cross-functional experience across biotech corporate strategy, business development, investor relations, and clinical operations. Prior to Capstan, Miguel was Vice President of Corporate Development and Investor Relations at Silverback Therapeutics, where he played a key role in the company’s Series C financing, IPO, and merger activities. Earlier in his career, he held progressively more senior corporate development and operational roles at multiple biopharmaceutical companies, including Synthorx, where he contributed to the company’s acquisition by Sanofi, as well as Acadia Pharmaceuticals and Ignyta. Miguel holds an MBA from the University of Chicago Booth School of Business and a BS in Microbiology, Immunology, and Molecular Genetics from UCLA.
Sessions
-
22-Jun-202630DEFrom Startup to $2B+ Exit: Lessons from Capstan’s Sale to AbbVie
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}